Acesso livre
Acesso livre

Saúde Pública/Medicina Humanitária

Dados mostram que a eficácia da vacina da Pfizer/BioNTech contra Covid cai para 84% depois de 6 meses.

2 Ago, 2021 | 17:35h

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show – STAT

Estudo original (preprint): Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine – medRxiv

 

Comentário no Twitter (fio – clique para saber mais)

 

CDC muda as diretrizes para uso de máscaras em resposta à ameaça da variante Delta da Covid-19.

2 Ago, 2021 | 17:06h

Comentário: CDC changes mask guidance in response to threat of Delta variant of Covid-19 – CNN

Ver diretriz: Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage – Centers for Disease Control and Prevention

 

Comentários no Twitter

 

Casos muito raros da síndrome de trombose com trombocitopenia (STT) após vacina AstraZeneca – A estimativa de STT após a primeira dose foi de 8,1 por milhão de vacinas; depois da segunda dose, a estimativa foi de 2,3 por milhão de vacinas.

2 Ago, 2021 | 17:05h

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet

Conteúdos relacionados:

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.

Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.

Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

 

Comentário no Twitter

 

Editorial | 9 lições aprendidas com a pandemia da Covid-19 para a melhoria dos cuidados hospitalares e dos serviços de saúde.

2 Ago, 2021 | 17:02h

Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery – JAMA Internal Medicine

Relatório | Engenheiros afirmam que melhorias na ventilação são essenciais para o uso seguro de espaços públicos.

2 Ago, 2021 | 16:59h

Comunicado de imprensa: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers – Royal Academy of Engineering

Relatório: Infection Resilient Environments: Buildings that keep us healthy and safe – National Engineering Policy Centre

Conteúdos relacionados:

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

 

Comentário no Twitter

 

Transmissão domiciliar do SARS-CoV-2 por crianças e adolescentes.

2 Ago, 2021 | 16:54h

Household Transmission of SARS-CoV-2 from Children and Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Study: Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity

A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters

Report: SARS-CoV-2 setting-specific transmission rates. Households showed the highest transmission rates (21.1%). Asymptomatic infections do occur but much less efficiently than symptomatic infection.

CDC Report: Transmission of SARS-COV-2 infections in households

The household secondary attack rate of SARS-CoV-2: A rapid review

 

Comentário no Twitter

 

OMS relata progresso na luta contra a epidemia de tabaco – Novas ameaças ao progresso têm sido causadas pelos novos produtos de tabaco e nicotina.

2 Ago, 2021 | 16:49h

Comunicado de imprensa: WHO reports progress in the fight against tobacco epidemic – World Health Organization

Relatório: WHO report on the global tobacco epidemic 2021: New and Emerging Products – World Health Organization

Comentário: While Global Tobacco Control Measures Improve, Electronic Cigarettes Evade Regulation in Many Countries – Health Policy Watch

 

Comentário no Twitter (fio – clique para saber mais)

 

Amazon e Google estão finalmente enfrentando um dos maiores problemas da atenção à saúde: dados de saúde não estruturados.

2 Ago, 2021 | 16:40h

Amazon And Google Are Finally Tackling One Of Healthcare’s Biggest Problems: Unstructured Health Data – Forbes

[Preprint] Covid-19: intervalo mais longo entre as doses da vacina da Pfizer aumenta a resposta imune.

27 Jul, 2021 | 10:34h

Comunicado de imprensa: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University

Estudo original (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine

Comentários:

Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ

Expert reaction to preprint from PITCH study looking at interval between two Pfizer vaccine doses, and antibody and T-cell responses – Science Media Centre

Conteúdo Relacionado:

Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (vários textos sobre o tema)

Outro estudo mostra resposta imune aumentada com vacinação heteróloga Oxford-AstraZeneca/mRNA.

27 Jul, 2021 | 10:32h

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine

Comentário: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine

Conteúdos Relacionados:

WHO warns against mixing and matching COVID vaccines.

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.